Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.42 |
| ▸ | DHODH | Q02127 | 6/20 | 0.39 |
| ▸ | GRK6 | P43250 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | CTSA | P10619 | 4/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037152 | 1.00 | KMO (0.42) | KMODHODHGRK6IDO1CTSA | |
| SCHEMBL25552003 | 0.89 | MBNL1 (0.47) | KMODHODHMBNL1 | |
| SCHEMBL30037130 | 0.89 | MBNL1 (0.47) | KMODHODHMBNL1 | |
| SCHEMBL25559956 | 0.88 | JAK2 (0.42) | IDO1JAK2GABRA5PTPN11MBNL1 | |
| SCHEMBL25551949 | 0.85 | CTSA (0.39) | IDO1CTSAJAK2GABRA5 | |
| SCHEMBL30036962 | 0.85 | CTSA (0.39) | IDO1CTSAJAK2GABRA5 | |
| SCHEMBL25242428 | 0.83 | KMO (0.51) | KMODHODHGRK6CTSA | |
| SCHEMBL30036520 | 0.80 | MBNL1 (0.39) | IDO1CTSAPTPN11MBNL1 | |
| SCHEMBL25551944 | 0.80 | MBNL1 (0.39) | IDO1CTSAPTPN11MBNL1 | |
| SCHEMBL30037588 | 0.80 | DHODH (0.41) | KMODHODHMBNL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| CN-115515940-A | Inhibitors of receptor interacting protein kinase I for the treatment of disease | 德州大学系统董事会 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | KMO 3071/4885DHODH 4384/4885GRK6 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.